Can a simpler dosing method for MRSA work just as well?

NCT ID NCT04793152

Disease control Sponsor: Anthony Bai Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a simpler way of dosing the antibiotic vancomycin (targeting a trough level of 10-15 mg/L) works as well as the more complex method (targeting AUC/MIC 400-600) for treating serious MRSA infections. About 700 adults with infections like bloodstream, lung, or bone infections will be randomly assigned to one of the two dosing strategies. The main goal is to see if the simpler method is not worse at preventing death or treatment failure within 90 days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 700 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients with serious MRSA infections based on culture results including bacteremia, pneumonia, pleural space infection, central nervous system infection, bone infection, septic arthritis, prosthetic joint infection, and deep abscess * Enrolment within 4 days from date of MRSA culture collection * Patient either currently not on vancomycin or has received vancomycin for 4 days or less Exclusion Criteria: * Vancomycin minimum inhibitory concentration (MIC) ≥2ug/mL * Patient is palliative or expected to die in the next 48 hours, or requires critical care resources but will not receive it due to advanced care directives * History of type 1 hypersensitivity reaction to vancomycin * Patients on intermittent hemodialysis or peritoneal dialysis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MRSA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

methicillin-resistant staphylococcus aureus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MRSA

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

4 sites. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Can a simpler dosing method for MRSA work just as well?

What the study statuses mean